Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Tries Out New Selling Strategy With Yervoy Launch

Executive Summary

Bristol-Myers Squibb is using a "new customer model" that takes a holistic approach to supporting Yervoy (ipilimumab), CEO Lamberto Andreotti told analysts on the company's first-quarter earnings call on April 28.

You may also be interested in...

BMS/AZ’s Komboglyze A Non-Starter At IQWiG For Diabetes Type 2

IQWiG of Germany has rejected Bristol/AstraZeneca’s Komboglyze for diabetes type 2 on procedural grounds, including use of the wrong comparator. The watchdog’s decision should induce manufacturers to negotiate early with health technology assessment bodies.

Bristol's Yervoy Bursts Out Of The Gate

The first-in-class immunotherapy for metastatic melanoma generated $95 million in its first full quarter on the market, exceeding management's expectations.

With Yervoy Approved in Europe, Bristol Activates Reimbursement Talks

BMS hopes that compelling survival data and unmet need will accelerate European patients' access to its novel advanced melanoma drug Yervoy.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts